Altigen Communications, Inc. (PNK:ATGN) Q3 2023 Earnings Call Transcript
Operator: Greetings. Welcome to the Altigen Communications Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode.
Stay updated with breaking news from Neil Cataldi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Greetings. Welcome to the Altigen Communications Third Quarter Fiscal Year 2023 Results Conference Call. At this time all participants are in a listen-only mode.
Carolyn David: Thank you, operator. Hello, everyone, and welcome to Altigen Communications Earnings Call for the Second Quarter Fiscal 2023.
New Study Demonstrates Bryostatin Normalizes Autistic Spectrum Behaviors in Mice - Peer Reviewed Article Published through Nature.com News provided by Share this article Share this article NEW YORK, Jan. 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced a new report published by "Scientific Reports," an open-access journal publishing peer reviewed research through Nature.com, titled "Chronic Bryostatin-1 rescues autistic and cognitive phenotypes in the fragile X mice." This new study, in collaboration with the Fragile X Foundation and s...
Press release content from PR Newswire. The AP news staff was not involved in its creation. Synaptogenix Announces $14.0 Million Private Placement January 21, 2021 GMT NEW YORK, Jan. 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. (the “Company” or Synaptogenix) (OTCQX: SNPX), formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securities purchase agreements with accredited investors to raise approximately $14.0 million in a private placement of common stock and warrants exercisable for common stock. In the private placement, the Company has agreed to sel...